We successfully developed a method to let OVs wear ROS-responsive anti-PD-1 and alendronate clothes (PD-1/Al@OV) to enhance T cell activity and prevent the OVs from being engulfed by TAMs for improving immunotherapeutic efficacy against GBM. This evidence concerns the gene PDCD1 and glioblastoma.